Review
Open access
Sep 2026
Lessons learned from clinical trials of thymic stromal lymphopoietin (TSLP) inhibition.
Type 2 (T2) immune-mediated epithelial-driven diseases are characterized by dysregulated immune responses at epithelial barrier surfaces. A key mediator of these diseases is thymic stromal lymphopoietin (TSLP), an epithelial cytokine that acts as a regulator of both T2 and non-T2 inflammation. TSLP activates dendritic...
J. Corren, L. Borish, C. Brightling et al.
· Journal of Allergy and Clini... · 0 citations